MarketVIEW Endemic and Diarrhoeal Vaccines  ·  September 2016 edition

Cholera Vaccines
Forecast

Cholera transmission is inseparable from water and sanitation failure, and the disease is now resurgent on a scale not seen in over a decade, with 60 countries reporting cases in 2024 and sustained high case counts through 2025 and into 2026, driven by conflict, flooding and weakened WASH infrastructure. That surge has collided with a severe, multi-year shortage in global oral cholera vaccine supply, forcing a switch from the standard two-dose regimen to single-dose campaigns. This report separates and models the two distinct markets this creates: a Western traveler-vaccine market served by Valneva's Dukoral and Bavarian Nordic's Vaxchora, and an endemic/global-stockpile market now being reshaped by EuBiologics' Euvichol-Plus and Euvichol-S and the WHO's October 2025 re-prequalification of Shanchol.

60+ Countries Reporting Cases Global OCV Stockpile Shortage Traveler vs Endemic Market Split Two-Scenario Forecast to 2035
Product catalogue
VAMV069
September 2016 edition

Format
Executive presentation + 2 Excel models
Coverage
Western traveler-origin markets + endemic/stockpile markets
Forecast horizon
To 2035
Approach
Two-scenario traveler demand model + endemic/stockpile review
Base edition
September 2016
Availability
Syndicated / bespoke
2.86M
Cholera cases estimated
annually in 69 endemic countries
1.3bn
People estimated to be at risk
of cholera worldwide
60
Countries reporting cholera
cases in 2024, the most in over a decade
3
WHO-prequalified OCVs now
supplying the global stockpile
Disease background

A water-borne disease now resurgent on a global scale

Cholera is a rapidly dehydrating diarrhoeal disease whose entire epidemiology is a function of water and sanitation infrastructure. This review sets out the pathogen's biology and clinical course before turning to the outbreak surge and vaccine supply crisis now defining the market.

WHO 2024-26 outbreak & stockpile data

Pathogen overview - Vibrio cholerae

Cholera is caused by ingestion of Vibrio cholerae, a Gram-negative bacterium most commonly acquired via the toxigenic O1 serogroup, with O139 as a secondary cause. Once established in the small intestine, toxigenic strains secrete cholera toxin (CT), which locks the intestinal adenylate cyclase enzyme into a persistently active state. The resulting surge in cyclic AMP drives massive, unregulated secretion of chloride, bicarbonate and water into the gut lumen, producing the disease's hallmark "rice water" stools. In severe cases this can cause the loss of many litres of fluid a day, leading to rapid dehydration, hypovolaemic shock and death within hours if untreated with oral or intravenous rehydration.

Transmission is overwhelmingly a marker of water and sanitation failure. The bacterium spreads via the faecal-oral route, principally through drinking water contaminated with faecal matter, and secondarily through contaminated food. Cholera therefore concentrates wherever safe water access and sanitation infrastructure break down: informal settlements, conflict zones, refugee and displacement camps, and areas hit by flooding or other climate-related disasters. Cholera is relatively rare among travellers to endemic countries, whose typically better access to safe food and water provides substantial protection, which is precisely why the vaccine market splits so cleanly into a small, high-value traveler segment and a much larger, price-sensitive endemic/humanitarian segment.

2021-26 has brought the sharpest global cholera resurgence in over a decade. The WHO's long-standing baseline estimate for endemic countries is approximately 2.86 million cases and 95,000 deaths a year across 69 endemic countries, with some 1.3 billion people considered at risk worldwide. Against that baseline, 60 countries reported cholera cases in 2024, up from 45 in 2023, with WHO tallying over 560,000 cases and more than 6,000 deaths for the year, a roughly 50% rise in fatalities compared with 2023. The elevated trajectory continued through 2025, with 614,828 cases and 7,598 deaths reported across five WHO regions for the full year, and into 2026, with 132,313 cases and 1,556 deaths reported as of late July. Sudan, Yemen, Afghanistan, Pakistan, the Democratic Republic of the Congo, Ethiopia and Nigeria have been among the hardest-hit countries, with conflict, mass displacement, flooding and the weakening of already-fragile WASH infrastructure repeatedly cited by WHO as the drivers of the upsurge.

2026 60+ countries active since 2024  |  614,828 cases / 7,598 deaths in 2025  |  global OCV stockpile under sustained pressure  |  single-dose strategy still in use
Product & competitor landscape

Two distinct vaccine markets, one shared manufacturing crisis

The traveler vaccine market and the endemic/stockpile market are served by entirely different products, companies and economics, but both now sit downstream of the same underlying constraint: global oral cholera vaccine manufacturing capacity has not kept pace with outbreak demand.

  • ValnevaMarketed - traveler market
    Dukoral Inactivated whole-cell + rCTB, two-dose oral
    Approved for travellers in the EU, Canada and Australia, Dukoral remains part of Valneva's core commercial portfolio. Valneva markets it directly across most territories, and from January 2026 CSL Seqirus has taken over marketing and distribution in Germany, replacing the distribution agreement Valneva had held with Bavarian Nordic since 2021.
  • Bavarian NordicMarketed - traveler market
    Vaxchora Live attenuated, single-dose oral
    The only FDA-approved cholera vaccine in the US, and also approved in the UK, EU and Australia. Bavarian Nordic acquired Vaxchora from Emergent BioSolutions in February 2023, for consideration of up to $380 million, as part of a wider travel-vaccine portfolio deal, and announced Vaxchora's commercial availability in Canada in September 2024. This is a material change since this report's original 2016 edition, when Vaxchora had only just reached the US market under PaxVax; note this update corrects the report's historical attribution of the brand to Emergent BioSolutions, its owner between the 2016 edition and 2023.
  • EuBiologicsWHO prequalified - global stockpile
    Euvichol-Plus & Euvichol-S Bivalent, killed whole-cell, two-dose OCV
    The South Korean manufacturer is now the dominant supplier to the WHO/ICG global OCV stockpile. Euvichol-S, a simplified, lower-cost second-generation formulation, received WHO prequalification in April 2024 and materially increased monthly stockpile deliveries. EuBiologics has been expanding capacity through the shortage, reporting production above 50 million doses in 2024, over 70 million in 2025 and a target above 90 million doses in 2026.
  • GCBC Vaccines (formerly Shantha)Re-prequalified October 2025
    Shanchol Bivalent, killed whole-cell, two-dose OCV
    Shanchol's original manufacturer, Shantha Biotechnics, discontinued production in 2022 and ceased supply by the end of 2023, removing a key stockpile contributor at the worst possible moment. Following an ownership change and a WHO on-site inspection, the vaccine regained WHO prequalification on 8 October 2025 under new manufacturer GCBC Vaccines Pvt Ltd, re-opening procurement through UNICEF, Gavi and PAHO and adding meaningful new capacity to the stockpile just as demand remains at record levels.
  • WHO / International Coordinating GroupStockpile under sustained pressure
    Global OCV stockpile shortage & single-dose strategy
    Manufacturing capacity has repeatedly failed to keep pace with outbreak demand since 2022, with the stockpile reported fully depleted at points, including October 2024. The ICG has maintained a single-dose strategy in most outbreak-response campaigns since October 2022, rather than the vaccine's approved two-dose schedule, to stretch limited supply across more people, even though single-dose protection is shorter-lived. Supply has been improving through 2025-26 as EuBiologics' capacity ramps and Shanchol re-enters the market, with some industry observers forecasting a "crowded market" by 2026-27, but the stockpile remains under real strain given the sustained scale of 2024-26 outbreak activity. WHO confirmed in February 2026 that annual OCV supply had risen to almost 70 million doses, enabling the first tranche of preventive, rather than purely reactive, campaigns since the 2022 shortage began; Bangladesh acted on that allocation in August 2026, launching a two-dose "Preventive Oral Cholera Vaccination Campaign-2026" targeting more than 5.1 million people across 14 high-risk upazilas and thanas before extending into Dhaka and four further districts, an early sign that recovering supply is allowing a partial return to preventive two-dose use alongside the ongoing single-dose outbreak-response default.
Report focus
2 markets, 1 crisis

The traveler market and the endemic/stockpile market look, on the surface, almost unrelated - yet both are shaped by the same manufacturing bottleneck. Dukoral and Vaxchora compete for a comparatively small, high-margin Western traveler segment where supply has never been the constraint; Euvichol-Plus, Euvichol-S and the newly re-prequalified Shanchol compete to refill a stockpile that has, at points, run to zero against the worst multi-year outbreak surge in over a decade. VacZine Analytics models both markets explicitly and separately, including two scenarios for how quickly global OCV manufacturing capacity closes the gap with outbreak demand.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report spanning both cholera vaccine markets, disease burden and the current outbreak and supply crisis, built on VacZine Analytics' long standing expertise in Endemic/Diarrhoeal diseases.

Western traveler-origin demand forecast

Value/volume demand modelling to 2035 for Dukoral and Vaxchora across major Western markets of traveler origin, with a country-of-origin build-up worksheet.

Endemic & global stockpile review

Full review of the WHO/ICG stockpile mechanics, Euvichol-Plus/S and Shanchol's re-prequalification, and their combined impact on future supply.

Two-scenario regulatory & supply modelling

Scenarios contrasting rapid versus constrained global OCV supply recovery, alongside Vaxchora's expanding footprint outside the US.

Competitor & pipeline review

Profiles of Valneva, Bavarian Nordic, EuBiologics and GCBC Vaccines, and the shifting ownership and supply landscape behind each product.

Disease burden & epidemiology

Updated global epidemiology review incorporating the 2024-26 outbreak surge, hardest-hit countries and the drivers behind it.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in cholera vaccine investment, supply planning and market entry.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the market-segment and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed models.

Market segmentGeographyVaccineStatusRevenue scenario
Traveler (outbound origin)Western EuropeDukoral (Valneva)MarketedModelled
Traveler (outbound origin)North AmericaVaxchora (Bavarian Nordic)MarketedModelled
Endemic / stockpileSub-Saharan AfricaEuvichol-Plus (EuBiologics)WHO prequalifiedModelled
███████████████████████████$██m (base)
███████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll vaccinesAll scenarios$███m
Full model in the licensed workbooks
Traveler-origin & endemic/stockpile markets · to 2035 · two scenarios
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and two fully interactive forecast models, built for organisations evaluating either or both sides of the cholera vaccine opportunity.

  • Executive presentation - disease background, current outbreak epidemiology, stockpile mechanics and full competitor landscape review
  • Two MS-Excel forecast models - a two-scenario Western traveler-origin demand model with a country-of-origin build-up worksheet, plus an endemic/stockpile review workbook
  • Wide market coverage - major Western markets of traveler origin, modelled alongside the endemic/global stockpile market
  • Competitor intelligence - Valneva's Dukoral, Bavarian Nordic's Vaxchora, EuBiologics' Euvichol-Plus/Euvichol-S and GCBC Vaccines' re-prequalified Shanchol
  • Updated epidemiology module - the 2024-26 global outbreak surge, hardest-hit countries and the WHO/ICG stockpile shortage and single-dose strategy
  • Early decision-making support - target market sizing and entry-timing guidance for both the traveler and endemic/stockpile opportunities
Target audience

Built for organisations across both cholera vaccine markets

Most valuable to teams assessing either the traveler-vaccine opportunity or the endemic/stockpile opportunity, and drawing on VacZine Analytics' long standing expertise in Endemic/Diarrhoeal diseases.

Vaccine manufacturers

Capacity planning and market-entry assessment for both the traveler and endemic/stockpile OCV segments, amid the ongoing supply shortage.

Corporate strategy & BD

Independent sizing of the traveler-vaccine opportunity and the commercial implications of new entrants such as GCBC Vaccines.

Investors & analysts

Independent assessment of ownership changes, supply risk and commercial upside across Valneva, Bavarian Nordic and the OCV manufacturers.

Public health, humanitarian & procurement bodies

Stockpile supply-and-demand modelling to support WHO, Gavi, UNICEF and national outbreak-response planning.

Travel health & occupational medicine providers

Up-to-date traveler-vaccine product comparisons and demand context for clinics and occupational health programmes.

Market access & policy

Pricing benchmarks and access-pathway assumptions spanning private traveler channels and public/humanitarian stockpile procurement.

About this analysis · VAMV069

VacZine Analytics has long standing expertise in Endemic/Diarrhoeal diseases, positioning us to reassess the cholera vaccine opportunity the moment the global outbreak surge and OCV supply shortage began reshaping both the traveler and endemic markets. This is a genuinely comprehensive analysis spanning major Western markets of traveler origin and the endemic/global stockpile market, and it has been well received by clients for the depth of its epidemiology, stockpile-mechanics and competitor review. Few groups have followed this historically underinvested market as closely, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in September 2016; any refresh would incorporate the current global outbreak surge, the WHO/ICG stockpile shortage and single-dose strategy, Shanchol's October 2025 re-prequalification under GCBC Vaccines, and Vaxchora's change of ownership to Bavarian Nordic. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV069 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc cholera vaccine analysis, a briefing call is included on request.